^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

VEGFA expression + FLT1 expression + KDR expression

i
Other names: VEGFA, Vascular endothelial growth factor A, VEGF, Vascular Endothelial Growth Factor A121, Vascular Endothelial Growth Factor A165, Vascular Endothelial Growth Factor, VEGF-A, MVCD1, FLT1, FLT, VEGFR1, Fms-related tyrosine kinase 1, KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor (a type III receptor tyrosine kinase)
Entrez ID:
Related biomarkers:
over1year
The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer. (PubMed, Diagnostics (Basel))
Kaplan-Meier analyses showed that patients with high VEGFA expression had significantly longer disease-free survival (p = 0.014) and overall survival (p = 0.009). This study was very informative, showing the implication of VEGF alterations in BC, suggesting that VEGFA and VEGFR2 expressions could be promising biomarkers for the better management of BC.
Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1)
|
VEGFA overexpression • KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
over1year
Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes. (PubMed, Oncol Lett)
The statistically significant difference in survival time of patients with high and low levels of VEGFR1 expression was revealed. VEGF-A/VEGFR1 expression may be important for risk evaluation of patients with MDS.
Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4) • VEGFD (Vascular Endothelial Growth Factor D) • VEGFC (Vascular Endothelial Growth Factor C)
|
VEGFA elevation • KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
2years
Establishment of an oral squamous cell carcinoma cell line expressing vascular endothelial growth factor a and its two receptors. (PubMed, J Dent Sci)
This triple-positive cell line showed no effect from a molecular targeted drug toward VEGF-A, but it did show strong cell growth inhibition in response to a VEGFR inhibitor. Thus, new therapeutic strategies against OSCC should include a VEGFR inhibitor.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1)
|
KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
over2years
VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop. (PubMed, Ann Diagn Pathol)
Whether or not it drives an oncogenic autocrine/paracrine loop in neoplastic cells, participating in an increased activation of signaling pathways downstream of tyrosine kinase receptors, including VEGFRs, is a tempting hypothesis. Nevertheless, the specific targeting of angiogenesis in MPNSTs may not be sufficient to slow down tumor growth.
Journal
|
NF1 (Neurofibromin 1) • KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1)
|
KDR expression • FLT1 overexpression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
over2years
HMGA2 promotes the migration and invasion of gallbladder cancer cells and HMGA2 knockdown inhibits angiogenesis via targeting VEGFA. (PubMed, Mol Med Rep)
In conclusion, the findings of the present study revealed that HMGA2 may promote GBC cell migration, invasion, EMT and angiogenesis. Therefore, inhibiting HMGA2 expression could be considered as a possible therapeutic approach for GBC.
Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • MMP2 (Matrix metallopeptidase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • CDH2 (Cadherin 2) • HMGA2 (High mobility group AT-hook 2) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
VEGFA overexpression • KDR expression • CD31 expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
almost3years
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. (PubMed, Cancer Res Treat)
A trend towards longer progression free survival (PFS) was detected univariately for patients with HER2-negative tumors and high expression of VEGFR2, (HR=0.60, p=0.059). VEGFR1 and VEGFR2 seem to have significant prognostic value in BC patients with metastatic disease treated with trastuzumab-based regimens.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C)
|
HER-2 positive • HER-2 negative • KDR overexpression • KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
|
Herceptin (trastuzumab) • trastuzumab biosimilar
over3years
FBXW7 inhibits invasion, migration and angiogenesis in ovarian cancer cells by suppressing VEGF expression through inactivation of β-catenin signaling. (PubMed, Exp Ther Med)
Overall, the results of the present study suggested that FBXW7 inhibited invasion, migration and angiogenesis of OC cells by suppressing VEGF expression through inactivation of β-catenin signaling. Thus, FBXW7 may be used as a novel therapeutic target for the treatment of OC.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KDR (Kinase insert domain receptor) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CDH1 (Cadherin 1) • FLT1 (Fms-related tyrosine kinase 1) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
MYC expression • KDR expression • CDH1 expression • CD31 expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
almost4years
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. (PubMed, J Mol Histol)
However, its role in malignant tumor progression may not be as crucial as expected. The value of comprehensive testing of the ligand and all receptors prior to administration of anti-angiogenic therapy needs to be evaluated in clinical trials.
Clinical • Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4) • NRP1 (Neuropilin 1)
|
KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
almost4years
Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma. (PubMed, Cancers (Basel))
Moreover, a positive interaction was found between the expression of VEGF-A, VEGFR-1, and VEGFR-2 in TILs and their serum levels (p = 0.002, p = 0.003, p = 0.003). In summary, these findings point to the usefulness of VEGF-A and its serum receptors assessment in clinical evaluation of cats with HER2-positive and TN Normal-Like tumors, suggesting that targeted therapies against these molecules may be effective for the treatment of these animals, as described in human breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1)
|
HER-2 positive • KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression • TILs
almost4years
Evaluation of a Brown Seaweed Extract from Dictyosiphon foeniculaceus as a Potential Therapeutic Agent for the Treatment of Glioblastoma and Uveal Melanoma. (PubMed, Mar Drugs)
VEGF was heterogeneously affected. The results in glioblastoma were not promising, but the anti-tumor properties in OMM-1 could make them interesting for further research concerning cancer diseases in the human eye.
Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1)
|
KDR expression • VEGFA expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
4years
Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors. (PubMed, Exp Mol Pathol)
The present study is the first to quantitatively analyze VEGFR1- and VEGFR2- positive tumor cells in various types of refractory brain tumors. This novel parameter significantly correlated with the progressive clinical courses.
Clinical • Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • CD34 (CD34 molecule)
|
KDR expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
4years
[VIRTUAL] Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2-negative MBC in NEWBEAT trial (WJOG9917BTR) (SABCS 2020)
Our analysis showed the different immune status depending stage, subtype and response in advanced breast cancer pts. The dynamic decrease of serum VEGF-A concentration and high expression of VEGFR-1 or VEGFR-2 in the immune suppressive cells in advanced breast cancer pts suggested that combination treatment with bevacizumab might clinically overcome the immune suppression via inhibition of VEGF-A. (UMIN000029590)
Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • ICOS (Inducible T Cell Costimulator)
|
HER-2 negative • EGFR overexpression • KDR expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression
|
Opdivo (nivolumab) • Avastin (bevacizumab) • paclitaxel
4years
HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma. (PubMed, Fertil Steril)
HMGA2-LM have a high vasculature density, which likely contributes to tumor growth and disease burden of this leiomyoma subtype. HMGA2 plays an important role in angiogenesis and the involvement of IGF2BP2-mediated pAKT activity in angiogenesis, which provides a potential novel target for therapy for this subtype of LM.
Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1)
|
KDR expression • FLT1 expression • VEGFA expression + FLT1 expression + KDR expression